Kymriah: England Becomes First In Europe To Say Yes To CAR-T
A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.
You may also be interested in...
UK Should Look To France To Speed Up Access To Innovative Medicines
Gilead suggests that the UK could take lessons from France on rapidly making innovative new treatments available after approval.
Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
NICE Head Sir Andrew Dillon To Stand Down
Sir Andrew Dillon is leaving his role as CEO of England’s health technology assessment body after 20 years.